Showing results (21-30 of 59) with videos related to
Sort By:
Pageof 6
Cancer Discovery|March 6, 2012
Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrenceDaniel V T Catenacci, Les Henderson, Shu-Yuan Xiao, et al.Epigenomics|March 4, 2014
Discovery and development of DNA methylation-based biomarkers for lung cancerKimberly Walter, Thomas Holcomb, Tom Januario, et al.Expert Opinion on Drug Discovery|May 27, 2014
Discovery and preclinical development of vismodegibStephen E Gould, Jennifer A Low, James C Marsters, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2012
A phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remissionStanley B Kaye, Louis Fehrenbacher, Robert Holloway, et al.Cancer Research|August 16, 2014
AXL inhibition sensitizes mesenchymal cancer cells to antimitotic drugsCatherine Wilson, Xiaofen Ye, Thinh Pham, et al.Molecular Cell|July 4, 1998
The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrixM Ohh, R L Yauch, K M Lonergan, et al.Molecular Cancer Therapeutics|March 29, 2013
HGF as a circulating biomarker of onartuzumab treatment in patients with advanced solid tumorsElicia Penuel, Congfen Li, Vaishali Parab, et al.The New England Journal of Medicine|June 8, 2012
Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndromeJean Y Tang, Julian M Mackay-Wiggan, Michelle Aszterbaum, et al.Journal of Pharmaceutical Sciences|April 17, 2026
SMARCA2 PROTAC-dendrimer conjugates for the treatment of non-small cell lung cancerMatthew O'Brien Laramy, Rosliana Halim, Summer Baker Dockrey, et al.Nature Communications|November 4, 2020
Functional characterization of SMARCA4 variants identified by targeted exome-sequencing of 131,668 cancer patientsTharu M Fernando, Robert Piskol, Russell Bainer, et al.Pageof 6